China puts down marker in diabetes, weight-loss drug research
Two phase III clinical studies of a China-developed weight-loss and diabetes drug have been published in Nature, representing a milestone for China’s growing presence in global metabolic disease research. The studies evaluated the impact of mazdutide, a dual GCG/GLP-1 receptor agonist developed by Innovent Biologics, on Chinese patients with type 2 diabetes. According to the…









